Genomic Health, Inc. (GHDX) COO Sells $159,300.00 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $31.86, for a total transaction of $159,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, August 8th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $30.57, for a total transaction of $152,850.00.
  • On Tuesday, July 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $32.53, for a total transaction of $162,650.00.

Genomic Health, Inc. (NASDAQ:GHDX) opened at 31.27 on Friday. The company’s market capitalization is $1.08 billion. The stock’s 50 day moving average is $30.90 and its 200 day moving average is $31.60. Genomic Health, Inc. has a 52 week low of $26.37 and a 52 week high of $33.97.

Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). The firm had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. Genomic Health’s revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.18) EPS. On average, equities research analysts expect that Genomic Health, Inc. will post ($0.01) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) COO Sells $159,300.00 in Stock” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://weekherald.com/2017/09/17/genomic-health-inc-ghdx-coo-sells-159300-00-in-stock.html.

GHDX has been the subject of several recent analyst reports. Canaccord Genuity lowered their price objective on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 15th. Jefferies Group LLC reaffirmed a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a research note on Monday, June 12th. Cowen and Company reaffirmed a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a research note on Friday, September 1st. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. Genomic Health presently has a consensus rating of “Hold” and an average price target of $32.00.

Several institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Genomic Health by 3.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock worth $516,000 after acquiring an additional 520 shares during the last quarter. State Street Corp lifted its holdings in shares of Genomic Health by 2.5% in the 2nd quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock worth $16,840,000 after acquiring an additional 12,696 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Genomic Health by 26.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock worth $12,070,000 after acquiring an additional 76,758 shares during the last quarter. Numeric Investors LLC lifted its holdings in shares of Genomic Health by 53.6% in the 2nd quarter. Numeric Investors LLC now owns 89,999 shares of the medical research company’s stock worth $2,929,000 after acquiring an additional 31,423 shares during the last quarter. Finally, Voya Investment Management LLC lifted its holdings in shares of Genomic Health by 18.5% in the 2nd quarter. Voya Investment Management LLC now owns 8,622 shares of the medical research company’s stock worth $281,000 after acquiring an additional 1,344 shares during the last quarter. Hedge funds and other institutional investors own 88.91% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply